Alison McVie‐Wylie

1.5k total citations
20 papers, 1.2k citations indexed

About

Alison McVie‐Wylie is a scholar working on Physiology, Rheumatology and Molecular Biology. According to data from OpenAlex, Alison McVie‐Wylie has authored 20 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Physiology, 9 papers in Rheumatology and 8 papers in Molecular Biology. Recurrent topics in Alison McVie‐Wylie's work include Lysosomal Storage Disorders Research (11 papers), Glycogen Storage Diseases and Myoclonus (9 papers) and Carbohydrate Chemistry and Synthesis (3 papers). Alison McVie‐Wylie is often cited by papers focused on Lysosomal Storage Disorders Research (11 papers), Glycogen Storage Diseases and Myoclonus (9 papers) and Carbohydrate Chemistry and Synthesis (3 papers). Alison McVie‐Wylie collaborates with scholars based in United States, Argentina and United Kingdom. Alison McVie‐Wylie's co-authors include Y.T. Chen, Andrea Amalfitano, Nina Raben, Joel Charrow, Russell E. Ware, John A. Phillips, Laura E. Case, Priya S. Kishnani, Joanne Mackey and Wendy E. Smith and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Neurology and Biochemical Journal.

In The Last Decade

Alison McVie‐Wylie

20 papers receiving 1.2k citations

Peers

Alison McVie‐Wylie
Motomichi Kosuga Japan
C B Whitley United States
Suma P. Shankar United States
Vũ Chí Dũng Vietnam
Elisabeth Young United Kingdom
Makiko Yasuda United States
Yasutsugu Chinen Japan
Glenn Cruse United States
Monica Cardone Italy
Aubryanna Hettinghouse United States
Motomichi Kosuga Japan
Alison McVie‐Wylie
Citations per year, relative to Alison McVie‐Wylie Alison McVie‐Wylie (= 1×) peers Motomichi Kosuga

Countries citing papers authored by Alison McVie‐Wylie

Since Specialization
Citations

This map shows the geographic impact of Alison McVie‐Wylie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison McVie‐Wylie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison McVie‐Wylie more than expected).

Fields of papers citing papers by Alison McVie‐Wylie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison McVie‐Wylie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison McVie‐Wylie. The network helps show where Alison McVie‐Wylie may publish in the future.

Co-authorship network of co-authors of Alison McVie‐Wylie

This figure shows the co-authorship network connecting the top 25 collaborators of Alison McVie‐Wylie. A scholar is included among the top collaborators of Alison McVie‐Wylie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison McVie‐Wylie. Alison McVie‐Wylie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Boye, Sanford L., Catherine R. O’Riordan, James Morris, et al.. (2022). Preclinical studies in support of phase I/II clinical trials to treat GUCY2D-associated Leber congenital amaurosis. Molecular Therapy — Methods & Clinical Development. 28. 129–145. 4 indexed citations
2.
Siders, William, Ronnie R. Wei, Alison McVie‐Wylie, et al.. (2016). GZ402668, a Next-Generation Anti-CD52 Antibody, Displays Decreased Proinflammatory Cytokine Release In Vitro (P3.068). Neurology. 86(16_supplement). 3 indexed citations
3.
Baek, Rena, Rachel Palmer, Robert J. Pomponio, et al.. (2016). The influence of a polymorphism in the gene encoding angiotensin converting enzyme (ACE) on treatment outcomes in late-onset Pompe patients receiving alglucosidase alfa. Molecular Genetics and Metabolism Reports. 8. 48–50. 8 indexed citations
4.
Kazi, Zoheb B., Ankit K. Desai, Angelika Erwin, et al.. (2016). Prophylactic immune modulation in infantile Ρompe disease using low-dose methotrexate induction: A safe, inexpensive, widely accessible, and efficacious strategy. Molecular Genetics and Metabolism. 117(2). S65–S66. 3 indexed citations
5.
Siders, William, Alison McVie‐Wylie, Vijay Dhawan, et al.. (2015). Characterization of a Next Generation Anti-CD52 Antibody (S20.006). Neurology. 84(14_supplement). 1 indexed citations
6.
Palermo, Amelia, R. E. Palmer, So Kubota, et al.. (2012). Transcriptional response to GAA deficiency (Pompe disease) in infantile-onset patients. Molecular Genetics and Metabolism. 106(3). 287–300. 16 indexed citations
7.
Nelson, Carol A., R. Bridge Hunter, William Weber, et al.. (2011). Inhibiting TGF-β Activity Improves Respiratory Function in mdx Mice. American Journal Of Pathology. 178(6). 2611–2621. 69 indexed citations
8.
Koeberl, Dwight D., Xiaoyan Luo, Baodong Sun, et al.. (2011). Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Molecular Genetics and Metabolism. 103(2). 107–112. 58 indexed citations
9.
Ashe, Karen H., Kristin M. Taylor, Qili Chu, et al.. (2011). Inhibition of Glycogen Biosynthesis via mTORC1 Suppression as an Adjunct Therapy for Pompe Disease. Clinical Therapeutics. 33(6). S31–S31. 2 indexed citations
10.
McVie‐Wylie, Alison, Hung Do, Russell Gotschall, et al.. (2008). Biochemical and pharmacological characterization of different recombinant acid α-glucosidase preparations evaluated for the treatment of Pompe disease. Molecular Genetics and Metabolism. 94(4). 448–455. 74 indexed citations
11.
Zhou, Qun, Srinivas Shankara, André Roy, et al.. (2007). Development of a simple and rapid method for producing non‐fucosylated oligomannose containing antibodies with increased effector function. Biotechnology and Bioengineering. 99(3). 652–665. 149 indexed citations
12.
Sun, Baodong, Haoyue Zhang, Daniel K. Benjamin, et al.. (2006). Enhanced Efficacy of an AAV Vector Encoding Chimeric, Highly Secreted Acid α-Glucosidase in Glycogen Storage Disease Type II. Molecular Therapy. 14(6). 822–830. 46 indexed citations
13.
Zhu, Yunxiang, Xuemei Li, Alison McVie‐Wylie, et al.. (2005). Carbohydrate-remodelled acid α-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Biochemical Journal. 389(3). 619–628. 91 indexed citations
14.
Wylie, Andrew A., David Pulford, Alison McVie‐Wylie, et al.. (2003). Tissue-Specific Inactivation of Murine M6P/IGF2R. American Journal Of Pathology. 162(1). 321–328. 50 indexed citations
15.
16.
17.
Amalfitano, Andrea, A. Resai Bengur, Richard P. Morse, et al.. (2001). Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial. Genetics in Medicine. 3(2). 132–138. 293 indexed citations
18.
Ding, Enyu, Bradley L. Hodges, Hsun‐Ming Hu, et al.. (2001). Long-Term Efficacy after [E1 - , polymerase - ] Adenovirus-Mediated Transfer of Human Acid-α-Glucosidase Gene into Glycogen Storage Disease Type II Knockout Mice. Human Gene Therapy. 12(8). 955–965. 50 indexed citations
19.
Amalfitano, Andrea, A. Resai Bengur, Richard P. Morse, et al.. (2001). Recombinant human acid ??-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial. Genetics in Medicine. 3(2). 132–138. 73 indexed citations
20.
Amalfitano, Andrea, Alison McVie‐Wylie, Hao Hu, et al.. (1999). Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-α-glucosidase. Proceedings of the National Academy of Sciences. 96(16). 8861–8866. 115 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Motomichi Kosuga Breakdown of academic impact, for papers by C B Whitley Breakdown of academic impact, for papers by Suma P. Shankar Breakdown of academic impact, for papers by Vũ Chí Dũng Breakdown of academic impact, for papers by Elisabeth Young Breakdown of academic impact, for papers by Makiko Yasuda Breakdown of academic impact, for papers by Yasutsugu Chinen Breakdown of academic impact, for papers by Glenn Cruse Breakdown of academic impact, for papers by Monica Cardone Breakdown of academic impact, for papers by Aubryanna Hettinghouse
Rankless by CCL
2026